Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease
Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease
This study is being conducted to determine whether treatment of obstructive sleep apnea (OSA)
 in patients with chronic kidney disease (CKD) improves kidney function. Half of the
 participants will receive continuous positive airway pressure (CPAP) treatment for their OSA
 in addition to their regular CKD treatment, while the other half will only receive their
 regular CKD treatment.
Obstructive sleep apnea (OSA) and associated hypoxemia during sleep have been associated with
 a decline in kidney function. The abnormalities in kidney function associated with OSA have
 been improved by treatment of OSA with continuous positive airway pressure (CPAP), which is a
 common and effective therapy for OSA. Up to now, clinical research on the impact of OSA on
 kidney function has been performed on patients without CKD. This study will examine the
 impact of CPAP therapy on kidney function in patients with CKD.

 CKD patients with OSA and nocturnal hypoxemia will be randomized into one of two groups where
 half will receive treatment of their OSA with CPAP and the other half will not. All
 participants will have kidney function monitored every 3 months for a year by measurement of
 serum creatinine and proteinuria. The change in estimated glomerular filtration rate (eGFR)
 and proteinuria between the two groups will be assessed to determine whether treatment of OSA
 improves kidney function in patients with CKD.
Inclusion Criteria:

 -  CKD stage 3 or 4

 -  OSA (RDI>5) and nocturnal hypoxemia (SaO2 <90% for >12% of night)

 Exclusion Criteria:

 -  Failure to meet inclusion criteria

 -  Current therapy with CPAP or supplemental oxygen

 -  Severe daytime sleepiness reflected by an Epworth Sleepiness Score >15

 -  Any driver who holds a commercial drivers' license or who reports a recent history
 (past 6 months) of a road traffic accident

 -  Severe nocturnal hypoxemia reflected by mean SaO2 <80% during level 3 sleep testing

 -  Daytime hypoxemia reflected by partial pressure of oxygen in arterial blood (PaO2)
 less than 60 millimetres of mercury (mmHg) during wakefulness

 -  Hypoventilation reflected by partial pressure of carbon dioxide in arterial blood
 (PaCO2) greater than 45 millimetres of mercury (mmHg) during wakefulness

 -  Central sleep apnea that accounts for >50% of the estimated RDI

 -  Unable to provide informed consent